STCube Resolves Legal Loss Issue and Focuses on New Drug Development... "Confident in Clinical Research Outcomes"

STCube is set to significantly enhance the competitiveness of its pipeline this year. After solidifying a strong financial foundation last year and achieving positive results in clinical trials for colorectal cancer and small cell lung cancer, the company will be officially removed from the management stock list following the submission of its audit report in March.

On the 19th, STCube announced through a disclosure that it resolved the criteria for designation as a management stock by achieving a pre-tax loss from continuing operations (hereafter referred to as pre-tax loss) ratio of 22.7% against equity capital for the 2024 fiscal year. According to KOSDAQ regulations, a listed company is designated as a management stock if the pre-tax loss ratio exceeds 50% more than twice in the last three years.

STCube secured a total of 81.4 billion KRW in clinical research funding through successful fundraising last year. This year, the company plans to accelerate clinical progress and focus on full-scale new drug development aimed at future license-out and partnerships. In particular, it will strengthen competitiveness in indications with high therapeutic potential such as colorectal cancer and lung cancer.

Jung Hyunjin, CEO of STCube, stated, “This year, we expect the results of our new drug development efforts to become visible in various areas,” adding, “We will demonstrate the clinical utility of Nelmastobat in the most promising therapeutic combinations and simultaneously seek optimal opportunities in the global market.”

He continued, “We would like to once again thank our shareholders who have trusted and waited for the company,” emphasizing, “We will establish a continuous new drug development system for our license-out strategy and do our utmost to enhance shareholder value and maximize corporate value.”

STCube is developing ‘Nelmastobat (hSTC810),’ the first-in-class immune checkpoint inhibitor in its category that blocks the new immuno-oncology target BTN1A1. BTN1A1-targeted therapy is expected to minimize anticancer side effects on normal cells and effectively suppress resistant and recurrent cancer cells, offering a new treatment option for cancer patients unresponsive to existing therapies.